These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 26352813)
21. A Case of Lysosomal Acid Lipase Deficiency Confirmed by Response to Sebelipase Alfa Therapy. Shen JJ; Davis JL; Hong X; Laningham FH; Gelb MH; Kim GE J Pediatr Gastroenterol Nutr; 2020 Dec; 71(6):726-730. PubMed ID: 32740531 [TBL] [Abstract][Full Text] [Related]
22. Sebelipase alfa enzyme replacement therapy in Wolman disease: a nationwide cohort with up to ten years of follow-up. Demaret T; Lacaille F; Wicker C; Arnoux JB; Bouchereau J; Belloche C; Gitiaux C; Grevent D; Broissand C; Adjaoud D; Abi Warde MT; Plantaz D; Bekri S; de Lonlay P; Brassier A Orphanet J Rare Dis; 2021 Dec; 16(1):507. PubMed ID: 34906190 [TBL] [Abstract][Full Text] [Related]
30. Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. Reiner Ž; Guardamagna O; Nair D; Soran H; Hovingh K; Bertolini S; Jones S; Ćorić M; Calandra S; Hamilton J; Eagleton T; Ros E Atherosclerosis; 2014 Jul; 235(1):21-30. PubMed ID: 24792990 [TBL] [Abstract][Full Text] [Related]
31. Lysosomal Acid Lipase Deficiency: Therapeutic Options. Pastores GM; Hughes DA Drug Des Devel Ther; 2020; 14():591-601. PubMed ID: 32103901 [TBL] [Abstract][Full Text] [Related]
32. Persistent dyslipidemia in treatment of lysosomal acid lipase deficiency. Pritchard AB; Strong A; Ficicioglu C Orphanet J Rare Dis; 2020 Feb; 15(1):58. PubMed ID: 32093730 [TBL] [Abstract][Full Text] [Related]
33. Clinical and Histologic Liver Improvement in Siblings With Lysosomal Acid Lipase Deficiency After Enzyme Replacement. Lyons H; Vouyoukas E; Higgins M; Maciejko JJ J Pediatr Gastroenterol Nutr; 2020 May; 70(5):635-639. PubMed ID: 32097366 [TBL] [Abstract][Full Text] [Related]
34. Screening for lysosomal acid lipase deficiency: A retrospective data mining study and evaluation of screening criteria. Draijer LG; Bosch AM; Wiegman A; Sjouke B; Benninga MA; Koot BGP Atherosclerosis; 2018 Nov; 278():174-179. PubMed ID: 30286343 [TBL] [Abstract][Full Text] [Related]
35. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Ferdinand KC; Davidson MH; Kelly MT; Setze CM Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674 [TBL] [Abstract][Full Text] [Related]
36. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300 [TBL] [Abstract][Full Text] [Related]
37. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Davidson MH; Donovan JM; Misir S; Jones MR Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413 [TBL] [Abstract][Full Text] [Related]
38. Successful sebelipase alfa desensitization in a pediatric patient. Kulhas Celik I; Kucukcongar Yavas A; Unal Uzun O; Siyah Bilgin B; Dibek Misirlioglu E; Gunduz M J Allergy Clin Immunol Pract; 2019 Feb; 7(2):732-733. PubMed ID: 30053591 [No Abstract] [Full Text] [Related]